Viridian Therapeutics (VRDN)
(Real Time Quote from BATS)
$17.43 USD
+0.14 (0.81%)
Updated Jul 30, 2024 10:20 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRDN 17.43 +0.14(0.81%)
Will VRDN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRDN
Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Other News for VRDN
Jefferies healthcare analyst holds an analyst/industry conference call
3 Biotech Names With Potential Catalysts By Year End
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
Viridian Therapeutics completes enrollment in THRIVE-2 trial
Buy Rating for Viridian Therapeutics on VRDN-001 Clinical Advancements and Market Potential